Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2007-10-23 Report Publication Anno…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Quarterly Investor Conference Call 1 page ?Kb
Report Publication Announcement Classification · 95% confidence The document is a media release announcing the upcoming release of Pharmaxis Ltd's September 2007 Quarterly Report and a related investor teleconference. It does not contain the actual quarterly report or substantive financial data but rather informs about the timing and details of the report release and conference call. The document length is short (1574 characters), and it explicitly states the report will be released the next day and the conference call will follow. This fits the pattern of a Report Publication Announcement (RPA) rather than the report itself or a call transcript. Therefore, the correct classification is RPA with high confidence.
2007-10-23 English
Pharmaxis Appoints Korean Distributor 2 pages ?Kb
Capital/Financing Update Classification · 90% confidence The document is a media release announcing the appointment of a Korean distributor for Pharmaxis' product Aridol, marking the first commercialisation step in Asia. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. It is a corporate announcement about a commercial partnership and market expansion. This type of document fits best under the category of Capital/Financing Update (CAP) as it relates to business development and commercialisation activities, which often fall under capital or financing updates in the absence of other more specific categories. The document length is 5658 characters, which is consistent with a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2007-10-17 English
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, and related agreements. It details the class and number of securities issued, issue price, purpose of the issue, and other related information. This type of document is specifically about capital raising and changes in the company's capital structure. It is not a full financial report, earnings release, or management discussion. It is a formal announcement of a capital/financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2007-10-15 English
Disclosure Under section 708A(5)(e) of the Corporations Act 1
Capital/Financing Update Classification · 95% confidence The document is a disclosure notice under section 708A(5)(e) of the Corporations Act 2001, relating to a recent share placement by Pharmaxis Ltd. It details the issuance and allotment of ordinary shares without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant provisions. This type of document is an announcement about a capital raising event and share issuance, not a full financial report or audit. It fits the category of Capital/Financing Update (CAP). The document length is short and focused on the share placement disclosure, confirming it is not a full report or regulatory filing. Therefore, the classification is CAP with high confidence.
2007-10-15 English
Becoming a substantial holder 5 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Notice of initial substantial holder filed pursuant to Section 671B of the Corporations Act 2001 (Cth). It details the substantial holding of shares by ABN AMRO Bank N.V. and related entities in Pharmaxis Ltd, including voting power, relevant interests, registered holders, consideration paid, and addresses. The document is a formal regulatory filing notifying the market and regulators about a change in substantial shareholding. It is not a financial report, earnings release, management report, or any other type of corporate report. It fits the definition of a Major Shareholding Notification (MRQ) as it reports changes in significant share ownership levels crossing thresholds.
2007-10-14 English
Share Placement and SPP 2 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an ASX media release dated 11 October 2007 announcing a placement of $50 million and a share purchase plan by Pharmaxis. It details the issuance of new shares, pricing, discounts, and the purpose of the capital raise. There is no financial statement or detailed financial report included, only an announcement of financing activity. The document length is 4234 characters, which is relatively short and consistent with a press release rather than a full financial report. The content clearly relates to capital raising and share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2007-10-10 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.